*License Level Clause Samples

*License Level. Unless otherwise set out on the Order Form the License Level for Software shall be “Named User” and Client shall ensure that no more User IDs than the number of Named User licenses set out on the Order Form are provided to any individuals and that the User IDs are not transferred from one individual to another. Without prejudice to the foregoing, to clarify, where an individual Named User’s User ID and password are deactivated and provided that the Fees have not been reduced as a result of such deactivation, Client may reassign such Named User access to a new User without incurring additional Fees. When the Order Form further identifies the User license is qualified as “Full”, “Contributor”, “Consumer” “Limited” or similar naming designations, such User will be limited to the functionality identified in the Documentation as available to that designated license qualification. 4.5. *Уровень Лицензии. Если иное не указано в Форме Заказа, Уровнем Лицензии на Программное обеспечение должна быть лицензия на «Индивидуального Пользователя», ▇▇▇▇▇▇ должен удостовериться, что количество Пользовательских идентификаторов не превышает количества лицензий на «Индивидуального Пользователя», установленных в Форме Заказа, и что Пользовательские идентификаторы не передаются от одного пользователя к другому. Без ущерба для вышеизложенного, в случае если Пользовательский идентификатор и пароль были деактивированы, и сумма Вознаграждений не была уменьшена в результате данной деактивации, Клиент может передать лицензию Индивидуального пользователя другому Пользователю Клиента, что не повлечет за собой увеличение суммы Вознаграждений. В случае если в Форме Заказа дополнительно указывается вид Индивидуальной лицензии: «Full», «Contributor», «Consumer», «Limited» или похожее название, использование Программного обеспечения Пользователем данной лицензии будет ограничено функциональностью указанной в документации к данному виду лицензии.
View Source

Related to *License Level

  • Service Level In the event that League InfoSight discovers or is notified by you of the existence of Non-Scheduled Downtime, we will use commercially reasonable efforts to determine the source of the problem and attempt to resolve it as quickly as possible.

  • License Scope Licensee is granted a non-exclusive, perpetual license to use, execute, reproduce, display, perform, or merge the Product within its business enterprise in the United States up to the maximum licensed capacity stated on the Purchase Order. Product may be accessed, used, executed, reproduced, displayed or performed up to the capacity measured by the applicable licensing unit stated on the Purchase Order (i.e., payroll size, number of employees, CPU, MIPS, MSU, concurrent user, workstation). Licensee shall have the right to use and distribute modifications or customizations of the Product to and for use by any Authorized Users otherwise licensed to use the Product, provided that any modifications, however extensive, shall not diminish Licensor’s proprietary title or interest. No license, right or interest in any trademark, trade name, or service ▇▇▇▇ is granted hereunder.

  • Service Levels All service level requirements will be set forth in Exhibit A (“▇▇▇▇.▇▇▇ Referral Service Level Requirements”). Recipient ▇▇▇▇▇▇ agrees to adhere, and encourage Recipient Agent’s adherence, with the version of the ▇▇▇▇.▇▇▇ Referral Service Level Requirements in effect at the time ▇▇▇▇.▇▇▇ identifies the Referral to Recipient Broker/Agent.

  • Service Level Expectations Without limiting any other requirements of the Agreement, the Service Provider shall meet or exceed the following standards, policies, and guidelines:

  • Royalty Rates As further consideration for the rights granted to AbbVie hereunder, subject to Section 6.7.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory, on a Licensed Product-by-Licensed Product basis, AbbVie shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Territory of each Licensed Product containing the same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] but equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] [*] The royalty tiers set forth in the table above shall only aggregate Licensed Products that contain the same Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Licensed Compound in the Territory during a Calendar Year are [*], and Net Sales for all Licensed Products containing a different Licensed Compound in the Territory during such Calendar Year are [*], then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]. With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdiction, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.1.